Evidence map›Paper›PMID 29385990›Full record

Trial reportBMC complementary and alternative medicine2018

Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial.

Niikee Schoendorfer, Nita Sharp, Tracey Seipel, Alexander G Schauss, Kiran D K Ahuja

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02396160 (The Effect of Urox™), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02396160 nacompletednot on this map

The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence

TypeinterventionalSponsorThe University of QueenslandRan2013 to 2015Enrolled150ConditionsOveractive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, NocturiaArmsUrox, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Niikee SchoendorferSchool of Medicine, University of Queensland, Herston, Australia.
Nita SharpSchool of Medicine, University of Queensland, Herston, Australia.
Tracey SeipelOccidental Medicine Department, Endeavour College of Natural Health, Brisbane, Queensland, Australia.
Alexander G SchaussBio5 Institute, Office of Research, Discovery and Innovation, and College of Science, University of Arizona; and, AIBMR Life Sciences, Seattle, Washington, USA.
Kiran D K AhujaSchool of Health Sciences, University of Tasmania, Locked Bag 1322, Launceston, Tasmania, 7250, Australia. Kiran.Ahuja@utas.edu.au.ORCID http://orcid.org/0000-0002-0323-4692

Funding

Seipel Group, Brisbane, Australia NA
6 · The paper itself

Abstract

backgroundStorage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI.

methodsEfficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm's test to account for repeated measures, and included an intention-to-treat analysis.

resultsOne hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment.

conclusionsThe outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians.

trial registrationNCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).

Indexed as

AgedCapparaceaeEquisetumFemaleHumansLinderaMaleMedical RecordsMiddle AgedPhytotherapyPlant ExtractsUrinary Bladder, OveractiveUrinary IncontinenceUrinationUrological AgentsPlant ExtractsUrological AgentsIncontinenceNocturiaOveractive bladderPhytomedicineUrgency

Identifiers

PMID29385990
PMCPMC5793427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.